The Glutamate Ionotropic Receptor AMPA Type Subunit pipeline drugs market research report outlays comprehensive information on the Glutamate Ionotropic Receptor AMPA Type Subunit targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Glutamate Ionotropic Receptor AMPA Type Subunit pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Respiratory, Metabolic Disorders, and Toxicology which include the indications Major Depressive Disorder, Treatment Resistant Depression, Respiratory Depression (Hypoventilation), Central Sleep Apnea, Obesity, and Poisoning. It also reviews key players involved in Glutamate Ionotropic Receptor AMPA Type Subunit targeted therapeutics development with respective active and dormant or discontinued products.
The Glutamate Ionotropic Receptor AMPA Type Subunit pipeline targets constitutes close to 33 molecules. Out of which, approximately 32 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 7, 5, 16, and 2 respectively. Similarly, the universities portfolio in Phase I comprises 1 molecule.
Glutamate Ionotropic Receptor AMPA Type Subunit overview
Glutamate ionotropic receptor AMPA type subunits are integral membrane proteins that form a central ion channel pore. The AMPA receptor is a ligand-gated ionotropic glutamate receptor. AMPA receptor antagonists are anticonvulsants used in patients with epilepsy in the treatment of partial-onset seizures.
For a complete picture of Glutamate Ionotropic Receptor AMPA Type Subunit’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
